Actively Recruiting

Phase Not Applicable
Age: 16Years +
All Genders
ID07271264

A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy for Dysplasia Detection in IBD Surveillance

Led by London North West Healthcare NHS Trust · Updated on 2026-04-13

219

Participants Needed

1

Research Sites

16 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to compare two imaging techniques, Texture and Colour Enhancement Imaging (TXI) and high-definition white light endoscopy, for detecting dysplasia in patients with inflammatory bowel disease (IBD) undergoing surveillance colonoscopy. TXI improves texture, brightness, and colour in white-light endoscopy to highlight subtle tissue differences and has shown potential value in predicting ulcerative colitis relapse and detecting lesions. However, no randomized data exist to confirm its effectiveness for dysplasia detection in IBD surveillance, prompting this randomized paired design study. Participants in the study will be randomly assigned to undergo withdrawal using either TXI or high-definition white light endoscopy following standardized protocols. The study compares the proportion of patients with at least one dysplastic lesion detected by each method. Both imaging techniques are performed during surveillance colonoscopy to evaluate their ability to identify dysplasia in the colon. During the study, participants will undergo surveillance colonoscopy with one of the two imaging methods. Researchers will monitor and compare dysplasia detection rates within six months. The primary outcome measure is the proportion of patients with at least one dysplastic lesion detected by TXI versus white light endoscopy. Participants will be evaluated for safety and the study will continue until March 2029, with assessments conducted according to the study schedule.

CONDITIONS

Brief Title

A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy

Who Can Participate

Age: 16Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients over 16 years old with inflammatory bowel disease undergoing surveillance colonoscopy
  • Patients with Crohn's disease involving more than 50% of the colon (L2/L3 Montreal classification)
  • Patients with ulcerative colitis with extensive or left-sided disease (E3 or E2 Montreal classification) for at least 8 years
  • Patients with primary sclerosing cholangitis along with IBD
  • Ability to give informed consent and willingness to participate
Not Eligible

You will not qualify if you...

  • Disease duration less than 8 years unless diagnosed with primary sclerosing cholangitis
  • Incomplete colonoscopy procedure
  • Bowel preparation score (BBPS) less than 6 or less than 2 in any colon segment
  • Mayo Endoscopic Score (MES) 2 or higher, or any SES-CD variable 2 or higher, or stenosis longer than 10 cm above the rectum
  • Previous colorectal surgery
  • Low platelet count below 50 or blood clotting problems preventing biopsy
  • Use of blood thinners not properly stopped before the procedure
  • Pregnancy
  • Unable or unwilling to give informed consent or participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Single procedure visit

Participants undergo surveillance colonoscopy using either Texture and Colour Enhancement Imaging (TXI) or high-definition white light endoscopy to detect dysplasia.

1 visit (in-person)

Long-term Monitoring

Duration - 6 months

Participants are monitored for up to 6 months following the colonoscopy to assess dysplasia detection outcomes.

Follow-up visits as per routine care

Trial Site Locations

Total: 1 location

1

Central Middlesex Hospital

London, United Kingdom, NW10 7NS

Actively Recruiting

Loading map...

Research Team

J

Jonathan Landy, Consultant Gastroenterologist

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Similar Trials

Conception of a Diagnosis, Prognosis and Therapeutic Decisio...

Autoimmune Lymphoproliferative Syndrome

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here